IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
CONCLUSIONS: These findings identify HER2 as a biomarker for IRX4204 treatment response and demonstrate a novel use of RXR agonists to synergize with current anti-HER2 therapies. Furthermore, our results suggest that RXR agonists can be useful for the treatment of anti-HER2 resistant and metastatic HER2-positive breast cancer.PMID:38578278 | DOI:10.1158/1078-0432.CCR-23-3839 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 5, 2024 Category: Cancer & Oncology Authors: Cassandra L Moyer Amanda Lanier Jing Qian Darian Coleman Jamal Hill Vidyasagar Vuligonda Martin E Sanders Abhijit Mazumdar Powel H Brown Source Type: research
Stabilizing tumor resident mast cells restores T cell infiltration and sensitizes sarcomas to PD-L1 inhibition
CONCLUSIONS: Our study suggests the targeting of MCs with clinically administered drugs, such as antihistamines, as a promising approach to overcome resistance to immunotherapy in sarcomas.PMID:38578281 | DOI:10.1158/1078-0432.CCR-24-0246 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 5, 2024 Category: Cancer & Oncology Authors: Myrofora Panagi Fotios Mpekris Chrysovalantis Voutouri Andreas G Hadjigeorgiou Chloe Symeonidou Eleni Porfyriou Christina Michael Andreas Stylianou John D Martin Horacio Cabral Anastasia Constantinidou Triantafyllos Stylianopoulos Source Type: research
New means and challenges in the targeting of BTK
Clin Cancer Res. 2024 Apr 5. doi: 10.1158/1078-0432.CCR-23-0409. Online ahead of print.ABSTRACTBruton's tyrosine kinase (BTK) is central to the survival of malignant and normal B-lymphocytes and has been a crucial therapeutic target of several generations of kinase inhibitors and newly developed degraders. These new means for targeting BTK have added additional agents to the armamentarium for battling cancers dependent on B-cell receptor (BCR) signaling, including chronic lymphocytic leukemia and other non-Hodgkin lymphomas. However, the development of acquired resistance mutations to each of these classes of BTK inhibitor...
Source: Clinical Cancer Research - April 5, 2024 Category: Cancer & Oncology Authors: Vindhya Nawaratne Anya K Sondhi Omar Abdel-Wahab Justin Taylor Source Type: research
Safety and preliminary efficacy of pembrolizumab following trans-arterial chemoembolization for hepatocellular carcinoma: the PETAL phase Ib study
CONCLUSIONS: TACE plus pembrolizumab was tolerable with no evidence of synergistic toxicity, encouraging further clinical development of immunotherapy alongside TACE.PMID:38578610 | DOI:10.1158/1078-0432.CCR-24-0177 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 5, 2024 Category: Cancer & Oncology Authors: David J Pinato Antonio D'Alessio Claudia Angela Maria Fulgenzi Alexandra Emilia Schlaak Ciro Celsa Saskia Killmer Jesus Miguens Blanco Caroline Ward Charalampos-Vlasios Stikas Mark R Openshaw Nicole Acuti Georgios Nteliopoulos Cristina Balcells Hector C K Source Type: research
Co-occurring EGFR p.E709X mutation Mediates Primary Resistance to the Third-generation EGFR-TKIs in EGFR p.G719X-mutant Patients with Advanced NSCLC
CONCLUSION: Co-occurring EGFR p.E709X mutation mediates primary resistance to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients but remained sensitive to afatinib. A personalized treatment strategy should be undertaken based on the co-existing EGFR p.E709X mutation status.PMID:38578683 | DOI:10.1158/1078-0432.CCR-23-3302 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 5, 2024 Category: Cancer & Oncology Authors: Lanlan Pang Yihua Huang Weitao Zhuang Yaxiong Zhang Jun Liao Yue Hao Feng Hao Guoqian Wang Ze-Xin Chase Chen Yu Zhu Mengzhen Li Zhengbo Song Bo Peng Deng Jing Li Li Zhang Wenfeng Fang Source Type: research
IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
CONCLUSIONS: These findings identify HER2 as a biomarker for IRX4204 treatment response and demonstrate a novel use of RXR agonists to synergize with current anti-HER2 therapies. Furthermore, our results suggest that RXR agonists can be useful for the treatment of anti-HER2 resistant and metastatic HER2-positive breast cancer.PMID:38578278 | DOI:10.1158/1078-0432.CCR-23-3839 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 5, 2024 Category: Cancer & Oncology Authors: Cassandra L Moyer Amanda Lanier Jing Qian Darian Coleman Jamal Hill Vidyasagar Vuligonda Martin E Sanders Abhijit Mazumdar Powel H Brown Source Type: research
Stabilizing tumor resident mast cells restores T cell infiltration and sensitizes sarcomas to PD-L1 inhibition
CONCLUSIONS: Our study suggests the targeting of MCs with clinically administered drugs, such as antihistamines, as a promising approach to overcome resistance to immunotherapy in sarcomas.PMID:38578281 | DOI:10.1158/1078-0432.CCR-24-0246 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 5, 2024 Category: Cancer & Oncology Authors: Myrofora Panagi Fotios Mpekris Chrysovalantis Voutouri Andreas G Hadjigeorgiou Chloe Symeonidou Eleni Porfyriou Christina Michael Andreas Stylianou John D Martin Horacio Cabral Anastasia Constantinidou Triantafyllos Stylianopoulos Source Type: research
New means and challenges in the targeting of BTK
Clin Cancer Res. 2024 Apr 5. doi: 10.1158/1078-0432.CCR-23-0409. Online ahead of print.ABSTRACTBruton's tyrosine kinase (BTK) is central to the survival of malignant and normal B-lymphocytes and has been a crucial therapeutic target of several generations of kinase inhibitors and newly developed degraders. These new means for targeting BTK have added additional agents to the armamentarium for battling cancers dependent on B-cell receptor (BCR) signaling, including chronic lymphocytic leukemia and other non-Hodgkin lymphomas. However, the development of acquired resistance mutations to each of these classes of BTK inhibitor...
Source: Clinical Cancer Research - April 5, 2024 Category: Cancer & Oncology Authors: Vindhya Nawaratne Anya K Sondhi Omar Abdel-Wahab Justin Taylor Source Type: research
Safety and preliminary efficacy of pembrolizumab following trans-arterial chemoembolization for hepatocellular carcinoma: the PETAL phase Ib study
CONCLUSIONS: TACE plus pembrolizumab was tolerable with no evidence of synergistic toxicity, encouraging further clinical development of immunotherapy alongside TACE.PMID:38578610 | DOI:10.1158/1078-0432.CCR-24-0177 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 5, 2024 Category: Cancer & Oncology Authors: David J Pinato Antonio D'Alessio Claudia Angela Maria Fulgenzi Alexandra Emilia Schlaak Ciro Celsa Saskia Killmer Jesus Miguens Blanco Caroline Ward Charalampos-Vlasios Stikas Mark R Openshaw Nicole Acuti Georgios Nteliopoulos Cristina Balcells Hector C K Source Type: research
Co-occurring EGFR p.E709X mutation Mediates Primary Resistance to the Third-generation EGFR-TKIs in EGFR p.G719X-mutant Patients with Advanced NSCLC
CONCLUSION: Co-occurring EGFR p.E709X mutation mediates primary resistance to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients but remained sensitive to afatinib. A personalized treatment strategy should be undertaken based on the co-existing EGFR p.E709X mutation status.PMID:38578683 | DOI:10.1158/1078-0432.CCR-23-3302 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 5, 2024 Category: Cancer & Oncology Authors: Lanlan Pang Yihua Huang Weitao Zhuang Yaxiong Zhang Jun Liao Yue Hao Feng Hao Guoqian Wang Ze-Xin Chase Chen Yu Zhu Mengzhen Li Zhengbo Song Bo Peng Deng Jing Li Li Zhang Wenfeng Fang Source Type: research
IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
CONCLUSIONS: These findings identify HER2 as a biomarker for IRX4204 treatment response and demonstrate a novel use of RXR agonists to synergize with current anti-HER2 therapies. Furthermore, our results suggest that RXR agonists can be useful for the treatment of anti-HER2 resistant and metastatic HER2-positive breast cancer.PMID:38578278 | DOI:10.1158/1078-0432.CCR-23-3839 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 5, 2024 Category: Cancer & Oncology Authors: Cassandra L Moyer Amanda Lanier Jing Qian Darian Coleman Jamal Hill Vidyasagar Vuligonda Martin E Sanders Abhijit Mazumdar Powel H Brown Source Type: research
Stabilizing tumor resident mast cells restores T cell infiltration and sensitizes sarcomas to PD-L1 inhibition
CONCLUSIONS: Our study suggests the targeting of MCs with clinically administered drugs, such as antihistamines, as a promising approach to overcome resistance to immunotherapy in sarcomas.PMID:38578281 | DOI:10.1158/1078-0432.CCR-24-0246 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 5, 2024 Category: Cancer & Oncology Authors: Myrofora Panagi Fotios Mpekris Chrysovalantis Voutouri Andreas G Hadjigeorgiou Chloe Symeonidou Eleni Porfyriou Christina Michael Andreas Stylianou John D Martin Horacio Cabral Anastasia Constantinidou Triantafyllos Stylianopoulos Source Type: research
New means and challenges in the targeting of BTK
Clin Cancer Res. 2024 Apr 5. doi: 10.1158/1078-0432.CCR-23-0409. Online ahead of print.ABSTRACTBruton's tyrosine kinase (BTK) is central to the survival of malignant and normal B-lymphocytes and has been a crucial therapeutic target of several generations of kinase inhibitors and newly developed degraders. These new means for targeting BTK have added additional agents to the armamentarium for battling cancers dependent on B-cell receptor (BCR) signaling, including chronic lymphocytic leukemia and other non-Hodgkin lymphomas. However, the development of acquired resistance mutations to each of these classes of BTK inhibitor...
Source: Clinical Cancer Research - April 5, 2024 Category: Cancer & Oncology Authors: Vindhya Nawaratne Anya K Sondhi Omar Abdel-Wahab Justin Taylor Source Type: research
Safety and preliminary efficacy of pembrolizumab following trans-arterial chemoembolization for hepatocellular carcinoma: the PETAL phase Ib study
CONCLUSIONS: TACE plus pembrolizumab was tolerable with no evidence of synergistic toxicity, encouraging further clinical development of immunotherapy alongside TACE.PMID:38578610 | DOI:10.1158/1078-0432.CCR-24-0177 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 5, 2024 Category: Cancer & Oncology Authors: David J Pinato Antonio D'Alessio Claudia Angela Maria Fulgenzi Alexandra Emilia Schlaak Ciro Celsa Saskia Killmer Jesus Miguens Blanco Caroline Ward Charalampos-Vlasios Stikas Mark R Openshaw Nicole Acuti Georgios Nteliopoulos Cristina Balcells Hector C K Source Type: research
Co-occurring EGFR p.E709X mutation Mediates Primary Resistance to the Third-generation EGFR-TKIs in EGFR p.G719X-mutant Patients with Advanced NSCLC
CONCLUSION: Co-occurring EGFR p.E709X mutation mediates primary resistance to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients but remained sensitive to afatinib. A personalized treatment strategy should be undertaken based on the co-existing EGFR p.E709X mutation status.PMID:38578683 | DOI:10.1158/1078-0432.CCR-23-3302 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 5, 2024 Category: Cancer & Oncology Authors: Lanlan Pang Yihua Huang Weitao Zhuang Yaxiong Zhang Jun Liao Yue Hao Feng Hao Guoqian Wang Ze-Xin Chase Chen Yu Zhu Mengzhen Li Zhengbo Song Bo Peng Deng Jing Li Li Zhang Wenfeng Fang Source Type: research
